Literature DB >> 22947593

Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.

Cesar Alaniz1, Jason M Pogue.   

Abstract

In 2003, a retrospective trial comparing linezolid versus vancomycin in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) showed improved survival in the linezolid group. This led to the ZEPHyR (Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to Be Due to Methicillin-Resistant Staphylococcus aureus) trial comparing linezolid versus vancomycin for MRSA pneumonia, which showed a benefit for linezolid with respect to clinical response but without a survival advantage. Limitations of the study included unbalanced treatment groups at baseline and number of patients excluded to reach the per-protocol group. Results of the ZEPHyR trial do not support routine use of linezolid for the treatment of MRSA pneumonia.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22947593     DOI： 10.1345/aph.1R221

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN： 1060-0280            Impact factor:   3.154


  5 in total

1.  Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.

Authors:  Y-H Chen; C-Y Liu; W-C Ko; C-H Liao; P-L Lu; C-H Huang; C-T Lu; Y-C Chuang; S-M Tsao; Y-S Chen; Y-C Liu; W-Y Chen; T-N Jang; H-C Lin; C-M Chen; Z-Y Shi; S-C Pan; J-L Yang; H-C Kung; C-E Liu; Y-J Cheng; J-W Liu; W Sun; L-S Wang; K-W Yu; P-C Chiang; M-H Lee; C-M Lee; G-J Hsu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-18       Impact factor: 3.267

2.  Vancomycin and nephrotoxicity: just another myth?

Authors:  Stephen W Davies; Christopher A Guidry; Robin T Petroze; Tjasa Hranjec; Robert G Sawyer
Journal:  J Trauma Acute Care Surg       Date:  2013-11       Impact factor: 3.313

3.  An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Authors:  Richard R Watkins; Tracy L Lemonovich; Thomas M File
Journal:  Core Evid       Date:  2012-12-11

4.  Antibiotic Resistance Profiling of Staphylococcus aureus Isolated from Clinical Specimens in a Tertiary Hospital from 2010 to 2012.

Authors:  Alain C Juayang; Gemma B de Los Reyes; April Joy G de la Rama; Christine T Gallega
Journal:  Interdiscip Perspect Infect Dis       Date:  2014-09-03

5.  The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections.

Authors:  Jinjian Fu; Xiaohua Ye; Cha Chen; Sidong Chen
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.